This week in techniques

Approach	Summary	Licensing status	Publication and contact information
Drug platforms			
Theophylline-activated small interfering RNA expression platform	siRNAs fused to aptazymes could provide a platform for developing inducible siRNA therapeutics. Aptazymes are aptamers conjugated to a ribozyme. <i>In vitro</i> , human embryonic kidney cells exposed to theophylline activated an siRNA-aptazyme containing a theophylline-sensitive aptamer. Next steps include developing aptazymes that respond to other compounds and optimizing the siRNA-aptazyme constructs for <i>in vivo</i> applications. SciBX 2(37); doi:10.1038/scibx.2009.1426 Published online Sept. 24, 2009	Work unpatented; licensing status not applicable	Kumar, D. <i>et al.</i> <i>J. Am. Chem. Soc.</i> ; published online Sept. 10, 2009; doi:10.1021/ja905596t Contact: Yohei Yokobayashi, University of California, Davis, Calif. e-mail: yoko@ucdavis.edu